Does smoking impact dopamine neuronal loss in de novo Parkinson disease?
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 29059491.
- Also identified by DOI 10.1002/ana.25082.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study analyzed data from dopamine transporter (DAT) positron emission tomographic scans of 282 male patients with de novo Parkinson disease to investigate whether smoking impacts striatal dopamine neuronal degeneration. Mean DAT activity in the posterior (p = 0.016) and ventral putamen (p = 0.028) was higher in 44 current smokers in comparison to 105 ex-smokers and 133 never-smokers. The severity of baseline motor deficits and the longitudinal increases in levodopa-equivalent doses during follow-up were similar among the 3 groups. These results suggest that current smoking, but not past smoking, protects dopamine neuronal degeneration in the sensorimotor striatum with no additional clinical benefits. Ann Neurol 2017;82:850-854.
Medical subject headings
- Dopaminergic Neurons
- Nerve Degeneration
- Parkinson Disease
- Smoking